Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Agnieszka Janus & Tadeusz Robak. (2019) Moxetumomab pasudotox for the treatment of hairy cell leukemia. Expert Opinion on Biological Therapy 19:6, pages 501-508.
Read now
Read now
Anna Wolska-Washer, Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2017) Emerging antibody-drug conjugates for treating lymphoid malignancies. Expert Opinion on Emerging Drugs 22:3, pages 259-273.
Read now
Read now
Sakiko Yoshida, Emily Tuscano, Connie Duong, Jong Chung, Yueju Li, Laurel Beckett, Joseph M. Tuscano & Noriko Satake. (2017) Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia. Leukemia & Lymphoma 58:5, pages 1254-1257.
Read now
Read now
Tadeusz Robak, Anna Wolska & Pawel Robak. (2015) Potential breakthroughs with investigational drugs for hairy cell leukemia. Expert Opinion on Investigational Drugs 24:11, pages 1419-1431.
Read now
Read now
Prithviraj Bose, Michael S Batalo, Beata Holkova & Steven Grant. (2014) Bortezomib for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 15:16, pages 2443-2459.
Read now
Read now
Articles from other publishers (11)
Ritwik Maiti, Bhumika Patel, Nrupesh Patel, Mehul Patel, Alkesh Patel & Nirav Dhanesha. (2023) Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Archives of Pharmacal Research 46:5, pages 361-388.
Crossref
Crossref
Ashley Y. Choi, Miriam Manook, Danae Olaso, Brian Ezekian, Jaeberm Park, Kyle Freischlag, Annette Jackson, Stuart Knechtle & Jean Kwun. (2021) Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. Frontiers in Immunology 12.
Crossref
Crossref
Sikander Ailawadhi, Kevin R. Kelly, Robert A. Vescio, Sundar Jagannath, Jeffrey Wolf, Mecide Gharibo, Taimur Sher, Leyla Bojanini, Maurice Kirby & Asher Chanan-Khan. (2019) A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 19:1, pages 29-34.
Crossref
Crossref
Sarah Taplin, Kapil Vashisht, Markus Walles, David Calise, William Kluwe, Page Bouchard & Robert Johnson. (2018) Hepatotoxicity with antibody maytansinoid conjugates: A review of preclinical and clinical findings. Journal of Applied Toxicology 38:5, pages 600-615.
Crossref
Crossref
Daniel Merk & Manfred Schubert-Zsilavecz. 2017. Drug Selectivity. Drug Selectivity
207
245
.
Patrice Debré & Francis Galibert. (2017) Immunothérapie par anticorps monoclonaux : ingénierie, indications et perspectives. Bulletin de l'Académie Nationale de Médecine 201:7-9, pages 1023-1035.
Crossref
Crossref
Leonard Naymagon & Maher Abdul-Hay. (2016) Novel agents in the treatment of multiple myeloma: a review about the future. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
Jun Lu, Feng Jiang, Aiping Lu & Ge Zhang. (2016) Linkers Having a Crucial Role in Antibody–Drug Conjugates. International Journal of Molecular Sciences 17:4, pages 561.
Crossref
Crossref
J.M. Redman, E.M. Hill, D. AlDeghaither & L.M. Weiner. (2015) Mechanisms of action of therapeutic antibodies for cancer. Molecular Immunology 67:2, pages 28-45.
Crossref
Crossref
Michael Mian & Annalisa Chiappella. (2015) Changing treatment paradigms in lymphoma: new targets and new drugs. memo - Magazine of European Medical Oncology 8:3, pages 184-188.
Crossref
Crossref
Tadeusz Robak & Pawel Robak. 2015. Resistance to Immunotoxins in Cancer Therapy. Resistance to Immunotoxins in Cancer Therapy
89
128
.